Supplemental Methods

Clinical trial exclusion criteria
Clinical trials in patients contributing to label dose finding with efficacy and/or safety data were included in the review. Trials meeting the following criteria were excluded:
 Clinical trials for indications that were not included in the drug label and did not support the efficacy evaluation for the approved indication.
 Clinical trials in healthy subjects that did not contribute to either dose ranging or efficacy evaluation.
 Clinical trials conducted in special populations and clinical pharmacology studies that did not contribute to the efficacy evaluation in the general patient population (such as e.g. renal impairment studies).
 Ongoing trials for which no interim efficacy data was considered in the efficacy evaluation.
 Clinical trial extensions that were not pertinent to the efficacy evaluation.
 Registry database studies.
 Natural history studies.
Clinical trial classification
For clinical development programs initiated in patients that were not within oncology, the presence or lack of Phase III trial results (such as in e.g. development programs with accelerated approval designation) to support the efficacy assessment determined whether Phase II trials were classified as exploratory or confirmatory, respectively. If no Phase III trial results were included to support approval, approval relied on evidence from Phase II trials, and these were therefore considered confirmatory in this review.
Identification of clinical trials relevant to label dose finding
Clinical trials relevant to label dose finding were retrieved using the search terms "dose-ranging", "doseresponse", "dose-finding", "dose selection", "multiple dose", "Phase II", "Phase 2", "recommended Phase 2 dose" (oncology approvals), "RP2D" (oncology approvals), and "dose escalation" (oncology approvals) 
Supplemental Results
Clinical development paths
Fewer active RN doses were included in exploratory than in confirmatory development in 11% (6 of 56) of programs. Furthermore, 16% of programs initiated in healthy volunteers included the same number of active RN doses in exploratory development as in confirmatory development (ratio of 1:1).. Furthermore, 32% of development programs (12 programs initiated in healthy volunteers and 6 programs initiated in patients) introduced active RN doses in confirmatory development that were not studied in preceding exploratory trials.
The number of active RN doses in exploratory development was higher for development programs that did not introduce new active RN doses in confirmatory development compared to ones that did (median 6 vs. 4, p = 0.01). This may be explained by increased probability of already having included the suitable dose(s) for confirmatory development due to the larger pool of doses included in exploratory development.
Dose range in exploratory development was not found to affect the number of active RN doses in confirmatory development or the introduction of new active RN doses in confirmatory development (data not shown).
Dose-ranging trials a. Dose-escalation trials
Compared to the exploratory dose-ranging trials, dose-escalation trials on average included more active RN doses (median of 6), a wider dose range (median of 13.5-fold), and a smaller sample size (median of 39.5) (Table S3 ). This difference is most likely due to the low starting doses and small dose increments in doseescalation trials to evaluate drug tolerability, where a small number of patients is exposed to each dose level.
b. Dose spacing in exploratory dose-ranging trials
Spacing of doses is a crucial aspect of dose-ranging trial design. In the 46 reviewed exploratory dose-ranging trials, no predominant dose spacing design was identified, as both equidistant dose spacing, log dose spacing and other spacing designs were utilized ( Figure S2 ). Spacing between the highest and next-to-highest included active RN doses ranged from 20% to 80%.
c. Multiple exploratory trials relevant to label dose finding Twenty development programs (15 initiated in healthy volunteers and 5 initiated in patients) performed more than one exploratory trial relevant to dose finding. Three of these development programs did not conduct 5 these trials in a sequential manner, one did not report the number of active RN doses for these trials, and for one program it was not possible to characterize the chronology of clinical trials. In programs where exploratory trials relevant to dose finding were conducted sequentially, 47% (7 of 15) of development programs included fewer, 33% (5 of 15) included the same number and 20% (3 of 15) included more active RN doses compared to the first trial ( Figure S3 ). The majority of development programs (53%) studied active RN doses over a narrower dose range in sequential exploratory dose-ranging trials, and 60% of programs included doses of higher magnitude ( Figure S3 ).
Reasons for missing dose-exposure-response characterization in clinical development
Dose-response
Fifty-five percent (33 of 60) of approval packages included statements referring to the evaluation of a doseresponse relationship for efficacy. For the 27 development programs that did not report any such evaluation, the reason for not doing so was not stated in 17 of these, while the remaining contained statements indicating it was not feasible due to the use of individual dose titration or the study of a single dose in the mentioned clinical trials. Out of the 17 approval packages that did not specify a reason for not reporting evaluation of dose-response for efficacy, 16 investigated an exposure-response relationship for efficacy (11 of these approval packages were for oncology drugs).
Exposure-response
Sixty three percent (38 of 60) of approval packages reported evaluation of an exposure-response relationship for efficacy. Among the 22 approval packages that did not report such evaluation, 41% did not specify a reason, 32% specified it was due to inadequate or lacking pharmacokinetic data collection in relevant clinical trials, while the remaining specified that there was a large or complete amount of pharmacokinetic measurements below the analytical quantification limit or that the analysis was not regarded due to the deemed irrelevance of systemic exposure to drug effect. For the nine approval packages that did not state a reason for not reporting evaluation of exposure-response for efficacy, 3 had pharmacokinetic sampling during exploratory or confirmatory trials in clinical development, suggesting that this evaluation was feasible yet ultimately not performed and/or reported. In terms of dose selection for confirmatory trials, several relevant comments were identified in approval packages. In one case, the FDA suggested that the sponsor add a lower, previously unstudied, dose along 6 with the originally proposed dose due tolerability and response concerns (Table S1 , ID 3). This allowed for the subsequent approval of two active RN doses following the confirmatory trial, and it can be hypothesized that the addition of this possible titration dose may have aided in delivering positive efficacy and safety results in the pivotal confirmatory trial. Within the context of introducing new doses in confirmatory development, an approval package reported that due to conventional dosing within the therapeutic area, a dose based on body size was initially introduced in confirmatory development. However, a population PK analysis of these data revealed that body size did not affect drug PK, and the posology was therefore switched to a fixed dose during confirmatory development, with this new dose subsequently gaining FDA approval (Table S1 , ID 1013). Lastly, in one approval package, it was specified that the development program's dose-ranging study "could not meaningfully inform" dose selection for confirmatory trials, due to the inclusion of "only" two active doses and completion of the trial after the initiation of confirmatory trials, and thus could not sequentially inform clinical development (Table S1 , ID 14).
Based on confirmatory data in four different approval packages, the FDA recommended that studying doses of lower magnitude than the approved dose as part of post-marketing requirements may optimize the drug benefit-risk profile due to safety concerns (Table S1 ; IDs 1022, 1021, 28, and 31). Furthermore, in two drug approvals, the FDA suggested that doses of higher magnitude should be explored to potentially increase the benefit of the drug (Table S1 ; IDs 10 and 1010). These remarks emphasize the interest of the FDA in maximizing the benefit-risk potential of doses made available to patients based on available data. In regard to the efforts of sponsors in identifying the label dose, the apparent dissatisfaction from the FDA towards the lack or inadequacy of dose-response exploration in clinical development was mentioned in four drug approvals (Table S1 ; IDs 40, 1008, 14, 27). In these, either the proposed dose was empirically based on the dose of marketed drugs the sponsor deemed to be similar to their own, dose ranging was not performed altogether, or the performed dose ranging was not deemed adequate by the FDA. It should be noted that the respective drug doses showed an acceptable benefit-risk profile in registration trials supporting subsequent FDA approval. 
Supplemental Discussion
Clinical development paths
Twenty-seven percent of clinical development programs included fewer or the same number of active RN doses in exploratory development compared to confirmatory development (ratio ≤ 1:1). The latter finding does not align well with Learning versus Confirming, as it suggests that, for a substantial number of programs, learning occurs in confirmatory development to a greater or similar extent than in exploratory development.
Regarding the introduction of new active RN doses in confirmatory development, such practice can be speculated to carry significant risk and its success would be highly contingent on accurate and precise quantification of the dose-exposure-response relationship that allows for simulation of drug efficacy and/or safety with low uncertainty. However, a lower number of active RN doses was included in exploratory development of programs that introduced new active RN doses in confirmatory development, suggesting that further learning in confirmatory development may have been the aim. Furthermore, it is a possibility that exploratory development may have raised concerns that could only be addressed in confirmatory development, and hence a wider dose range was tested or a previously unstudied dose was introduced. The same reasoning may apply to development programs where fewer or the same number of active RN doses were included in exploratory development than in confirmatory development.
Dose-ranging trials
Of 15 clinical development programs that included multiple exploratory trials relevant to label dose finding, 53% evaluated a wider dose range in the initial trial(s) compared to the subsequent trial(s). This approach is supported by simulation studies showing that a wider dose range rather than many active doses covering a narrow dose range should ideally be studied in the initial dose-ranging trial 1 .
More learning in dose finding -why?
Since dose finding has perceivably not evolved to a significant extent in clinical drug development practice over the last two decades, what may be done to incite more sponsors to undertake studying more doses/wider dose ranges in dose-ranging trials and characterize dose-exposure-response through a model-based benefit/risk has not been optimized) increases the risk that a competitor drug will outperform the drug candidate in the market due to a better benefit/risk profile. Lastly, adequate dose finding in clinical development may reduce the risk of regulatory post-marketing requirements to improve drug benefit/risk.
Although not presently available, examples such as the latter may be the necessary elements to convince industry of the importance of thorough dose finding. In addition to incitements directed towards drug sponsors, Maloney recently proposed a new paradigm spawning from change in the regulatory approval of drugs, revolving around the continuous approval and re-evaluation of a dose range as opposed to a one-time approval of a single dose 8 . Such regulatory change would force sponsors to emphasize dose-exposureresponse characterization in all stages of clinical development, thereby putting model-based analysis and associated trial design at the forefront. The result-oriented mindset of drug development can also be thought to change significantly as a consequence of such regulatory change, as the goal of identifying the "single right dose" to obtain approval in the general patient population would no longer be relevant.
